AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15795184
Drug: Low-dose atropine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose atropine (LDA) 2 microg/kg
Trial: 12453930
Drug: Esmolol 1
RxNorm normalized name: esmolol 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1 mg kg(‐1) followed by 250 micro g kg(‐1) min(‐1)
Trial: 8507448
Drug: Cortisol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (50 mg orally, 6 hourly on days 5 to 10) with placebo (Study A)
Trial: 8507448
Drug: Cortisol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (50 mg orally, 6 hourly on days 5 to 10) with atenolol (50 mg orally, 12 hourly on days 1 to 10) (Study B)
Trial: 2886541
Drug: Intra-arterial dopamine
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial dopamine infusion after alpha-adrenoceptor blockade with phenoxybenzamine
Trial: 2886541
Drug: Intra-arterial dopamine
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial dopamine infusion
Trial: 2886541
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion after alpha-adrenoceptor blockade
Trial: 2886541
Drug: Sulpiride (vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (vascular dopamine receptor antagonist)
Trial: 31714470
Drug: FLS intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLS intervention with treatment including anti-osteoporosis medication.
Trial: 30283014
Drug: Oral targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral targeted therapies (ibrutinib, idelalisib, venetoclax)
Trial: 30283014
Drug: Next-generation anti-CD20
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Next-generation anti-CD20 monoclonal antibodies (obinutuzumab)
Trial: 30283014
Drug: Programmed death
RxNorm normalized name: Magnetic nanocarrier-conjugated small interfering RNA against programmed death ligand 1
DrugBank: TTX-siPDL1 (DB18550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed death 1 inhibitors (pembrolizumab, nivolumab)
Trial: 24879841
Drug: Sensor-augmented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented therapy (control)
Trial: 23503735
Drug: High-frequency chest
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency chest wall oscillation therapy
Trial: 31856900
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine gluconate-impregnated patch
Trial: 29268756
Drug: Allopurinol dose
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol dose escalation to achieve serum urate (SU) <6 mg/dl
Trial: 21550556
Drug: Paclitaxel/Carboplatin (PC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel/Carboplatin (PC) - paclitaxel at a dose of 140 mg/m² and carboplatin AUC3, administered on days 1 and 15
Trial: 21550556
Drug: Vinorelbine/Carboplatin (VC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine/Carboplatin (VC) - vinorelbine at a dose of 45 mg/m² orally and carboplatin AUC3, administered on days 1 and 15
Trial: 10595478
Drug: Baseline (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (no medication)
Trial: 31918452
Drug: Apatinib 250
RxNorm normalized name: lapatinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 250 mg once daily combined with EGFR-TKI
Trial: 31188514
Drug: Pulsed Radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Radiofrequency (PRF) treatment for 6 minutes
Trial: 28458049
Drug: Treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual control (n=47)
Trial: 25967124
Drug: Tri-iodothyronine (T3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-iodothyronine (T3) treatment
Trial: 18813917
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) injection (5 mug) into the tibialis anterior muscle
Trial: 18813917
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline injection (0.5 ml, 5.8%) into the left and right TA
Trial: 18813917
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection into the contralateral TA muscle
Trial: 16307026
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) and chemotherapy
Trial: 15001403
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg of oral phenytoin (PO), divided in maximum doses of 400 mg every two hours
Trial: 15001403
Drug: 18 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg/kg of intravenous phenytoin (IVP) at an initial infusion rate of 50 mg/min
Trial: 15001403
Drug: 18 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg/kg of intravenous fosphenytoin (IVF) at an initial infusion rate of 150 mg/min
Trial: 10698387
Drug: St Thomas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St Thomas cardioplegic solution (Control)
Trial: 17714967
Drug: GH 6
RxNorm normalized name: Zicam Cough 6 MG/ACTUAT Oral Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 6 microg/kg/d (higher dose)
Trial: 17714967
Drug: GH 3
RxNorm normalized name: Zicam Cough 3.3 MG/ACTUAT Oral Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 3 microg/kg/d (low dose)
Trial: 17225547
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine granules (1 package)
Trial: 17225547
Drug: Duxil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duxil (1 tablet)
Trial: 12953047
Drug: Prednisone at
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone at a dose of 60 mg/m2/day for 6 weeks, followed by 40 mg/m2/48 h for at least another 6 weeks
Trial: 12953047
Drug: Cyclophosphamide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (2 mg/kg/day for at least 8 weeks)
Trial: 12953047
Drug: Alternate day
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate day therapy of prednisone
Trial: 12953047
Drug: Single and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and divided dosing of prednisone
Trial: 12953047
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of relapse therapy
Trial: 8715742
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of medicines
Trial: 8715742
Drug: Previous studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous studies on self-administration
Trial: 3887543
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g/day for 21 days
Trial: 16919573
Drug: Poststress end-systolic
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poststress end-systolic volume (ESV) index greater than 27 mL/m2
Trial: 16919573
Drug: Poststress ESV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poststress ESV index of 27 mL/m2 or less
Trial: 11156644
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BT) injection (20 U) and subsequent daily applications of isosorbide dinitrate (ID) (2.5 mg three times daily for three months)
Trial: 11156644
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BT) injection only (20 U)
Trial: 7507304
Drug: Aprotinin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (2 x 10(6) KIU bolus followed by 5 x 10(5) KIU/h infusion until end of surgery
Trial: 28667231
Drug: Educational video
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational video about OSA and CPAP therapy
Trial: 21999887
Drug: SQ-standardized grass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-standardized grass allergy immunotherapy tablet (AIT)
Trial: 20178207
Drug: Carbamide peroxide
RxNorm normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamide peroxide treatment for 14 days
Trial: 27798291
Drug: Daily meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily meal delivery (n = 139)
Trial: 27798291
Drug: Once weekly,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly, frozen meal delivery (n = 106)
Trial: 24725445
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product (300 mg irbesartan tablet)
Trial: 24725445
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (300 mg irbesartan tablet)
Trial: 23734218
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) 0.8 mg / B12 0.4 mg with and without 40 mg B6
Trial: 16177808
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg THC
Trial: 9291340
Drug: Tenidap (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap (120 mg) daily for 6 weeks
Trial: 7686709
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 30 mg/kg i.v.
Trial: 17024692
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg DiaPep277
Trial: 17024692
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg DiaPep277
Trial: 17024692
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg DiaPep277
Trial: 8485271
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg q.d.s. for 12 weeks
Trial: 30892290
Drug: Guided bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided bone regeneration with dental implant placement (study group)
Trial: 27737534
Drug: Gemcitabine/Cisplatin (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/Cisplatin (GP) - Gemcitabine 1,250 mg/m2 on days 1 and 8, Cisplatin 75 mg/m2 on day 1 every 3 weeks
Trial: 27737534
Drug: Irinotecan/Cisplatin (IP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan/Cisplatin (IP) - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 1 and 8 every 3 weeks
Trial: 24671388
Drug: Ketamine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1.0 mg/kg in 20 ml of normal saline)
Trial: 24671388
Drug: Ketamine-levobupivacaine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine-levobupivacaine (0.5 mg/kg of ketamine plus 50.0 mg of 0.25% levobupivacaine in 20 ml of normal saline)
Trial: 24671388
Drug: Control (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (20 ml of intraarticular normal saline)
Trial: 21777715
Drug: Armodafinil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil (250 mg/d)
Trial: 12509398
Drug: CEE+MPA-cyclic (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE+MPA-cyclic (daily CEE and MPA at 10 mg/day on days 1-12)
Trial: 12509398
Drug: CEE+MPA-continuous (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE+MPA-continuous (daily CEE and MPA at 2.5 mg/day)
Trial: 12509398
Drug: CEE-MP (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE-MP (daily CEE and micronized progesterone at 200 mg/day on days 1-12)
Trial: 11025235
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) administered intravenously at up to 15 ng/kg/min for 72 hours after surgery
Trial: 11025235
Drug: Placebo (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isotonic saline) administered for the same duration
Trial: 8658340
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for eyelid dermatitis (specific treatments not detailed in the abstract)
Trial: 4096071
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (IV)
Trial: 24067260
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d THC
Trial: 24067260
Drug: 60 mg/d
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/d THC
Trial: 24067260
Drug: 120 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/d THC
Trial: 24067260
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg/d THC)
Trial: 23059145
Drug: d‐cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐cycloserine (50 mg)
Trial: 20613539
Drug: Intravenous lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lornoxicam
Trial: 16025322
Drug: Buprenorphine/naloxone 2/0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone 2/0.5 mg
Trial: 16025322
Drug: Buprenorphine/naloxone 8/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone 8/2 mg
Trial: 16025322
Drug: Buprenorphine/naloxone 32/8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone 32/8 mg
Trial: 16025322
Drug: Buprenorphine/naloxone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (all doses)
Trial: 1502490
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (Pepto-Bismol) - 2 tablets four times daily for 4 weeks
Trial: 1502490
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate combined with clindamycin - 2 weeks of 300 mg clindamycin four times daily
Trial: 6497564
Drug: Haloperidol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5 mg test dose; 10 mg maintenance dose)
Trial: 6497564
Drug: Thiothixene hydrochloride
RxNorm normalized name: Thiothixene Hydrochloride
DrugBank: Thiothixene (DB01623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiothixene hydrochloride (0.22 mg/kg test dose; 0.44 mg/kg maintenance dose)
Trial: 6497564
Drug: Haloperidol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5 mg test dose)
Trial: 26966825
Drug: Maitland's Central
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maitland's Central postero-anterior vertebral pressure for thoracic spine (T1-T8) in addition to individualized treatment for low back pain and home exercise program (HEP) of breathing exercises
Trial: 26966825
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment for low back pain and home exercise program (HEP) of breathing exercises
Trial: 24986816
Drug: A1 beta-casein
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A1 beta-casein milk (750 ml/day)
Trial: 24986816
Drug: A2 beta-casein
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A2 beta-casein milk (750 ml/day)
Trial: 20855362
Drug: Lasmiditan (2.5-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasmiditan (2.5-45 mg)
Trial: 20855362
Drug: Lasmiditan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasmiditan (20 mg and higher)
Trial: 17618954
Drug: Slow-release metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release metformin (SR)
Trial: 17618954
Drug: Regular-release metformin
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-release metformin (RR)
Trial: 11023477
Drug: GM‐CSF (sargramostim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF (sargramostim) 125 microgram/m(2) subcutaneously twice weekly for 6 months
Trial: 8228207
Drug: Ro 42‐5892
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 42‐5892 (600 mg orally, once a day)
Trial: 8228207
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg orally, once a day)
Trial: 2645889
Drug: Nalmefene, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene, 1.0 mg
Trial: 2645889
Drug: Naloxone, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone, 1.0 mg
Trial: 2645889
Drug: Saline, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline, 1.0 mL
Trial: 31894045
Drug: Minocycline hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline hydrochloride ointment
Trial: 29050998
Drug: Detomidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine (5 μg kg−1) with methadone (0.2 mg kg−1)
Trial: 29050998
Drug: Methadone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (0.2 mg kg−1) alone (MET)
Trial: 29050998
Drug: Detomidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine (5 μg kg−1) alone (DET)
Trial: 29050998
Drug: Detomidine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine (2.5 μg kg−1) with methadone (0.2 mg kg−1) (MLD)
Trial: 29050998
Drug: Detomidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine (5 μg kg−1) with methadone (0.2 mg kg−1) (MMD)
Trial: 29050998
Drug: Detomidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine (10 μg kg−1) with methadone (0.2 mg kg−1) (MHD)
Trial: 24107879
Drug: Adaptol, 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptol, 1500 mg daily divided into three doses for 8 weeks
Trial: 21300344
Drug: Anastrozole at
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole at 1 mg/d
Trial: 21300344
Drug: Anastrozole at
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole at 5 mg/d
Trial: 21300344
Drug: Anastrozole at
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole at 10 mg/d
Trial: 21300344
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate at 50 mg/d
Trial: 20209968
Drug: Placebo of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of starch capsules
Trial: 17009251
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day conjugated equine estrogens (estrogen-alone trial)
Trial: 17009251
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate (estrogen-plus-progestin trial)
Trial: 15504193
Drug: Ephedrine 70
RxNorm normalized name: guaifenesin-pseudoephedrine 700 mg-80 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 70 microg kg(‐1) administered intravenously 3 min before induction of anaesthesia.
Trial: 15504193
Drug: Saline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administered intravenously 3 min before induction of anaesthesia (Control Group II).
Trial: 9497795
Drug: Normoglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycaemia (blood glucose 5 mmol/l)
Trial: 9497795
Drug: Acute hyperglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hyperglycaemia (aimed at 15 mmol/l)
Trial: 9497795
Drug: Intrajejunal fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrajejunal fat administration (1 g/h) during normoglycaemia
Trial: 9497795
Drug: Intrajejunal fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrajejunal fat administration (1 g/h) during hyperglycaemia
Trial: 9497795
Drug: Fat administration
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat administration
Trial: 3745847
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose of liquid aluminum‐magnesium antacid (75 ml in five daily doses)
Trial: 27496239
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral feeding (liquid oral diet for 2 weeks with gradually expanding daily maximums)